{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T17:22:42Z","timestamp":1793467362083,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008746","name":"National Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008746","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.bbmt.2020.04.008","type":"journal-article","created":{"date-parts":[[2020,4,14]],"date-time":"2020-04-14T01:57:57Z","timestamp":1586829477000},"page":"1239-1246","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic"],"prefix":"10.1016","volume":"26","author":[{"given":"Veronika","family":"Bachanova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parastoo","family":"Dahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhagirathbhai","family":"Dholaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan A.","family":"Grupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Hayes-Lattin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9323-8007","authenticated-orcid":false,"given":"Murali","family":"Janakiram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard T.","family":"Maziarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph P.","family":"McGuirk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loretta J.","family":"Nastoupil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olalekan O.","family":"Oluwole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Riedell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2020.04.008_bib0001","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2020.04.008_bib0002","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2020.04.008_bib0003","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2020.04.008_bib0004","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2020.04.008_bib0005","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.bbmt.2019.12.108","article-title":"A multicenter retrospective analysis of outcomes and toxicities with commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed\/refractory aggressive B-cell lymphomas","volume":"26(suppl)","author":"Riedell","year":"2020","journal-title":"Biol Blood Marrow Transplant."},{"key":"10.1016\/j.bbmt.2020.04.008_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2019.100640","article-title":"Modern management of relapsed and refractory aggressive B-cell lymphoma: a perspective on the current treatment landscape and patient selection for CAR T-cell therapy","volume":"40","author":"Bachanova","year":"2020","journal-title":"Blood Rev"},{"key":"10.1016\/j.bbmt.2020.04.008_bib0007","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2020.04.008_bib0008","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.04.008_bib0009","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/blood-2016-01-694356","article-title":"Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy","volume":"128","author":"Bhoj","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.04.008_bib0010","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.jcyt.2017.06.001","article-title":"Building blocks for institutional preparation of CTL019 delivery","volume":"19","author":"McGuirk","year":"2017","journal-title":"Cytotherapy"},{"key":"10.1016\/j.bbmt.2020.04.008_bib0011","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.04.008_bib0012","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","article-title":"Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study","volume":"109","author":"Fielding","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.04.008_bib0013","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1038\/sj.leu.2404824","article-title":"Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial","volume":"21","author":"Tavernier","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2020.04.008_bib0014","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.3324\/haematol.2016.144311","article-title":"International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed\/refractory acute lymphoblastic leukemia","volume":"101","author":"G\u00f6kbuget","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2020.04.008_bib0015","series-title":"Yescarta\u2122 (axicabtagene ciloleucel) [package insert]","year":"2017"},{"key":"10.1016\/j.bbmt.2020.04.008_bib0016","series-title":"Kymriah\u2122 (tisagenlecleucel) [package insert]","year":"2017"},{"key":"10.1016\/j.bbmt.2020.04.008_bib0017","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1182\/blood-2018-99-114152","article-title":"Axicabtagene ciloleucel (axi-cel) CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed\/refractory large B-cell lymphoma: real world experience","volume":"132(suppl 1)","author":"Nastoupil","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.04.008_bib0018","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1182\/blood-2018-99-117199","article-title":"Axicabtagene ciloleucel in the real world: outcomes and predictors of response, resistance and toxicity","volume":"132(suppl 1)","author":"Jacobson","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.04.008_bib0019","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1182\/blood-2018-99-111368","article-title":"2-Year follow-up and high-risk subset analysis of Zuma-1, the pivotal study of axicabtagene ciloleucel (axi-cel) in patients with refractory large B cell lymphoma","volume":"132(suppl 1)","author":"Neelapu","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.04.008_bib0020","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/hon.117_2630","article-title":"Cytokine release syndrome and neurotoxicity by baseline tumor burden in adults with relapsed or refractory diffuse large B\u2010cell lymphoma treated with tisagenlecleucel","volume":"37","author":"Maziarz","year":"2019","journal-title":"Hematol Oncol."},{"key":"10.1016\/j.bbmt.2020.04.008_bib0021","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1182\/blood-2018-99-120013","article-title":"Safety of axicabtagene ciloleucel CD19 CAR T-cell therapy in elderly patients with relapsed or refractory large B-cell lymphoma","volume":"132(suppl 1)","author":"Sano","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.04.008_bib0022","doi-asserted-by":"crossref","first-page":"S202","DOI":"10.1016\/j.bbmt.2019.12.695","article-title":"Inpatient and intensive care unit resource utilization after CD19-targeted chimeric antigen receptor T-cell therapy (CART19) for pediatric acute lymphoblastic leukemia (ALL)","volume":"26(suppl)","author":"Myers","year":"2020","journal-title":"Biol Blood Marrow Transplant."},{"key":"10.1016\/j.bbmt.2020.04.008_bib0023","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1182\/blood-2019-129279","volume":"134(suppl 1)","author":"Grupp","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.04.008_bib0024","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/j.bbmt.2019.12.105","article-title":"Risk-adapted preemptive tocilizumab decreases severe cytokine release syndrome (CRS) after CTL019 CD19-targeted chimeric antigen receptor (CAR) T-cell therapy for pediatric B-cell acute lymphoblastic leukemia (B-ALL)","volume":"26(suppl)","author":"Myers","year":"2020","journal-title":"Biol Blood Marrow Transplant."},{"key":"10.1016\/j.bbmt.2020.04.008_bib0025","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1182\/blood-2019-130650","article-title":"Hospitalization patterns with commercial CAR T-cell therapy: a single institution experience","volume":"134(suppl 1)","author":"Dwivedy Nasta","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.04.008_bib0026","series-title":"Interim guidelines for COVID-19 management in hematopoietic cell transplant and cellular therapy patients, version 1.2","author":"Waghmare","year":"2020"},{"key":"10.1016\/j.bbmt.2020.04.008_bib0027","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/infdis\/jiu645","article-title":"Effect of corticosteroid therapy on influenza-related mortality: a systematic review and meta-analysis","volume":"212","author":"Rodrigo","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.bbmt.2020.04.008_bib0028","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(20)30317-2","article-title":"Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury","volume":"395","author":"Russell","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2020.04.008_bib0029","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0140-6736(20)30361-5","article-title":"On the use of corticosteroids for 2019-nCoV pneumonia","volume":"395","author":"Shang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2020.04.008_bib0030","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/978-1-4939-7568-6_8","article-title":"In vivo infection model of severe influenza A virus","volume":"1725","author":"Mansell","year":"2018","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.bbmt.2020.04.008_bib0031","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.19.01892","article-title":"Optimizing chimeric antigen receptor T-cell therapy for adults with acute lymphoblastic leukemia","volume":"38","author":"Frey","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.04.008_bib0032","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.04.008_bib0033","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy\u2014assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.04.008_bib0034","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41571-018-0075-2","article-title":"Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy","volume":"16","author":"Mahadeo","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.04.008_bib0035","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3324\/haematol.2019.229781","article-title":"Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)","volume":"105","author":"Yakoub-Agha","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2020.04.008_bib0036","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","article-title":"FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome","volume":"23","author":"Le","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.bbmt.2020.04.008_bib0037","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1182\/blood.2019001463","article-title":"Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy","volume":"134","author":"Gardner","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.04.008_bib0038","doi-asserted-by":"crossref","unstructured":"Favalli EG, Ingegnoli F, De Lucia O, Cincinelli G, Cimaz R, Caporali R. COVID-19 infection and rheumatoid arthritis: faraway, so close! Autoimmun Rev. https:\/\/doi.org\/10.1016\/j.autrev.2020.102523, accessed April 5, 2020. [e-pub ahead of print].","DOI":"10.1016\/j.autrev.2020.102523"},{"key":"10.1016\/j.bbmt.2020.04.008_bib0039","unstructured":"Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. 2020. ChinaXiv. 202003.200026."},{"key":"10.1016\/j.bbmt.2020.04.008_bib0040","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1182\/bloodadvances.2020001907","article-title":"First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab","volume":"4","author":"Zhang","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.bbmt.2020.04.008_bib0041","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1002\/art.10623","article-title":"Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial","volume":"46","author":"Choy","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.bbmt.2020.04.008_bib0042","first-page":"1426","article-title":"Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I\/II clinical study","volume":"30","author":"Nishimoto","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.bbmt.2020.04.008_bib0043","doi-asserted-by":"crossref","unstructured":"Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in critically ill patients in the Seattle region\u2014case series. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2004500, accessed April 5, 2020. [e-pub ahead of print]","DOI":"10.1056\/NEJMoa2004500"},{"key":"10.1016\/j.bbmt.2020.04.008_bib0044","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","article-title":"Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells","volume":"26","author":"Cordeiro","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.04.008_bib0045","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.1182\/bloodadvances.2019000717","article-title":"Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy","volume":"3","author":"Hill","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.bbmt.2020.04.008_bib0046","article-title":"Invasive mold infections after chimeric antigen receptor-modified T-cell therapy: a case series, review of the literature, and implications for prophylaxis","author":"Haidar","year":"2019","journal-title":"Clin Infect Dis"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879120302172?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879120302172?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:09:32Z","timestamp":1761059372000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879120302172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S1083879120302172"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2020.04.008","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2020.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}